FDA PDUFA Calendar
The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates. These are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
The FDA will typically issue one of the following decisions:
-
CRL - complete response letter - rejection letter noting reasons
-
Marketing approval - approved to market under the given label
Sometimes the FDA requires an advisory committee meeting prior to the approval decision. This meeting is a public discussion with committee members of various relevant backgrounds, which usually concludes in a vote regarding the efficacy and safety of the drug in question. The FDA is may use this discussion and vote as a guideline for their decision but by no means are bound to this discussion or vote.
Create a free account to search the FDA Catalyst Calendar or start your 7-day free trial of BPIQ Pro today for unlimited access and to see our Big Mover stocks to watch.
Ticker | Drug | Indication | PDUFA Date |
|---|---|---|---|
FBIO | CUTX-101 (Copper Histidinate) | Menkes Disease | June 30, 2025 |
REGN | Linvoseltamab (BCMAXCD3) | Multiple myeloma | July 10, 2025 |
RHHBY | Columvi® + GemOx | Diffuse large B-cell lymphoma (DLBCL) | Jul 20, 2025 |
REPL | RP1 +Opdivo (nivolumab) | Melanoma | Jul 22, 2025 |
ASND | TransCon hGH | Adult growth hormone deficiency | July 27, 2025 |
PTCT | Sepiapterin (PTC923) | PKU (Phenylketonuria) | July 29, 2025 |
REGN | Odronextamab | Follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) | July 30, 2025 |
INSM | Brensocatib (DPP1 inhibitor) | NCFBE (Non-Cystic Fibrosis Bronchiectasis) | August 12, 2025 |
TNXP | TNX-102 SL (Tonmya™) | FM (Fibromyalgia) | August 15, 2025 |
CMRX | Dordaviprone (ONC201) | recurrent H3 K27M-mutant diffuse glioma | August 18, 2025 |
*Want to see all the upcoming FDA catalyst events? Check out our FDA Catalyst Calendar

